organization · Reporting owner
Foresite Capital VI-A, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Eikon Therapeutics, Inc.
Report date February 04, 2026 · Filed February 06, 2026
Jointly reported with Foresite Capital Management IV, LLC, Foresite Capital Fund IV, L.P., Foresite Capital Management V, LLC, Foresite Capital Fund V, L.P., Foresite Capital Opportunity Management V, LLC, Foresite Capital Opportunity Fund V, L.P., Foresite Capital VI-A Management, LLC
Section 16 reporting ended · disclosed 2026-02-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,340,878 |
Reported balance
After 2026-02-04 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-02-04 · Conversion · Acquired 1,340,878 · Balance 1,340,878 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,676,399 |
Reported balance
After 2026-02-04 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-02-04 · Conversion · Acquired 335,521 · Balance 1,676,399 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,714,254 |
Reported balance
After 2026-02-04 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-02-04 · Conversion · Acquired 37,855 · Balance 1,714,254 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,943,682 |
Reported balance
After 2026-02-04 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-02-04 · Conversion · Acquired 229,428 · Balance 1,943,682 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 697,885 |
Reported balance
After 2026-02-04 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2026-02-04 · Conversion · Acquired 697,885 · Balance 697,885 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 735,740 |
Reported balance
After 2026-02-04 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2026-02-04 · Conversion · Acquired 37,855 · Balance 735,740 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 737,366 |
Reported balance
After 2026-02-04 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2026-02-04 · Conversion · Acquired 1,626 · Balance 737,366 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 804,573 |
Reported balance
After 2026-02-04 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2026-02-04 · Conversion · Acquired 67,207 · Balance 804,573 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,263,428 |
Reported balance
After 2026-02-04 transaction · row 9
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 9 · 2026-02-04 · Conversion · Acquired 458,855 · Balance 1,263,428 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 348,942 |
Reported balance
After 2026-02-04 transaction · row 10
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 10 · 2026-02-04 · Conversion · Acquired 348,942 · Balance 348,942 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 386,797 |
Reported balance
After 2026-02-04 transaction · row 11
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 11 · 2026-02-04 · Conversion · Acquired 37,855 · Balance 386,797 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 387,719 |
Reported balance
After 2026-02-04 transaction · row 12
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 12 · 2026-02-04 · Conversion · Acquired 922 · Balance 387,719 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 425,852 |
Reported balance
After 2026-02-04 transaction · row 13
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 13 · 2026-02-04 · Conversion · Acquired 38,133 · Balance 425,852 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 408,725 |
Reported balance
After 2026-02-04 transaction · row 14
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 14 · 2026-02-04 · Conversion · Acquired 408,725 · Balance 408,725 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F5: The shares are held of record by Foresite Capital VI-A, LLC ("Fund VI-A"). Foresite Capital VI-A Management, LLC ("FC VI-A Management") is the general partner of Fund VI-A and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FC VI-A Management, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund VI-A, disclaims beneficial ownership of the shares held by Fund VI-A, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,318,983 |
Reported balance
After 2026-02-04 transaction · row 15
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 15 · 2026-02-04 · Purchase · Acquired 55,555 · Balance 1,318,983 F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-02-04 · Conversion · Disposed 10,000,000 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-02-04 · Conversion · Disposed 2,502,252 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2026-02-04 · Conversion · Disposed 5,204,684 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2026-02-04 · Conversion · Disposed 2,602,342 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Series B-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2026-02-04 · Conversion · Disposed 282,317 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. |
| Series B-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2026-02-04 · Conversion · Disposed 282,317 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Series B-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2026-02-04 · Conversion · Disposed 282,317 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Series B-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · 2026-02-04 · Conversion · Disposed 3,048,192 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F5: The shares are held of record by Foresite Capital VI-A, LLC ("Fund VI-A"). Foresite Capital VI-A Management, LLC ("FC VI-A Management") is the general partner of Fund VI-A and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FC VI-A Management, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund VI-A, disclaims beneficial ownership of the shares held by Fund VI-A, except to the extent of such person's pecuniary interest in such securities. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · 2026-02-04 · Conversion · Disposed 12,123 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · 2026-02-04 · Conversion · Disposed 6,878 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 26
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 26 · 2026-02-04 · Conversion · Disposed 501,219 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 27
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 27 · 2026-02-04 · Conversion · Disposed 284,392 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 28
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 28 · 2026-02-04 · Conversion · Disposed 1,711,025 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 29
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 29 · 2026-02-04 · Conversion · Disposed 3,422,051 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $43.59 · Expires 2030-02-14 | IndirectSee Footnote | 17,092 |
Reported balance
Holding disclosure · report date 2026-02-04 · row 30
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 30 · Balance 17,092 F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $43.59 · Expires 2030-02-14 | IndirectSee Footnote | 34,185 |
Reported balance
Holding disclosure · report date 2026-02-04 · row 31
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 31 · Balance 34,185 F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.
F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.
F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.
F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.
F5: The shares are held of record by Foresite Capital VI-A, LLC ("Fund VI-A"). Foresite Capital VI-A Management, LLC ("FC VI-A Management") is the general partner of Fund VI-A and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FC VI-A Management, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund VI-A, disclaims beneficial ownership of the shares held by Fund VI-A, except to the extent of such person's pecuniary interest in such securities.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries D Preferred Stock · Derivative | 3,422,051 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 29 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 458,855 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries D Preferred Stock · Derivative | 1,711,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 28 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 229,428 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2 · ownership.nature: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries C-1 Preferred Stock · Derivative | 284,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 27 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 38,133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4 · ownership.nature: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries C-1 Preferred Stock · Derivative | 501,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 26 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 67,207 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries C Preferred Stock · Derivative | 6,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 25 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 922 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4 · ownership.nature: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries C Preferred Stock · Derivative | 12,123 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 24 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,626 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries B-1 Preferred Stock · Derivative | 3,048,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 23 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 408,725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F5 · ownership.nature: The shares are held of record by Foresite Capital VI-A, LLC ("Fund VI-A"). Foresite Capital VI-A Management, LLC ("FC VI-A Management") is the general partner of Fund VI-A and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FC VI-A Management, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund VI-A, disclaims beneficial ownership of the shares held by Fund VI-A, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries B-1 Preferred Stock · Derivative | 282,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 22 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 37,855 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4 · ownership.nature: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries B-1 Preferred Stock · Derivative | 282,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 21 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 37,855 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries B-1 Preferred Stock · Derivative | 282,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 20 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 37,855 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2 · ownership.nature: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries A-1 Preferred Stock · Derivative | 2,602,342 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 19 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 348,942 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4 · ownership.nature: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries A-1 Preferred Stock · Derivative | 5,204,684 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 18 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 697,885 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries A-1 Preferred Stock · Derivative | 2,502,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 17 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 335,521 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2 · ownership.nature: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries A Preferred Stock · Derivative | 10,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · derivative · entry 16 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,340,878 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2 · ownership.nature: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | PurchaseCommon Stock | 55,555 | $18.00 | $999,990.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 15 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,318,983 F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 408,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 14 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 408,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F5 · ownership.nature: The shares are held of record by Foresite Capital VI-A, LLC ("Fund VI-A"). Foresite Capital VI-A Management, LLC ("FC VI-A Management") is the general partner of Fund VI-A and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FC VI-A Management, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund VI-A, disclaims beneficial ownership of the shares held by Fund VI-A, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 38,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 13 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 425,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4 · ownership.nature: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 922 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 12 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 387,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4 · ownership.nature: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 37,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 11 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 386,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4 · ownership.nature: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 348,942 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 10 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 348,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4 · ownership.nature: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 458,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 9 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,263,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 67,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 8 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 804,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 1,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 7 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 737,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 37,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 6 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 735,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 697,885 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 5 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 697,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3 · ownership.nature: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 229,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 4 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,943,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2 · ownership.nature: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 37,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 3 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,714,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2 · ownership.nature: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 335,521 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 2 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,676,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2 · ownership.nature: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 19:37 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 1,340,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011662 · tm265543-1_4seq1.xml · nonDerivative · entry 1 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital VI-A Management, LLC · CIK 0001899218 · 10% owner Foresite Capital VI-A, LLC · CIK 0001899120 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,340,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2 · ownership.nature: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.